174 related articles for article (PubMed ID: 25528831)
1. [Pathogenesis, diagnosis and treatment of hepatic encephalopathies in patients with liver cirrhosis].
Moĭseienko VO; Manzhaliĭ EH; Solonovych OS; Nykula TD
Lik Sprava; 2014 Nov; (11):39-47. PubMed ID: 25528831
[TBL] [Abstract][Full Text] [Related]
2. L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic.
Butterworth RF
Drugs; 2019 Feb; 79(Suppl 1):1-3. PubMed ID: 30706421
[No Abstract] [Full Text] [Related]
3. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition.
Ndraha S; Hasan I; Simadibrata M
Acta Med Indones; 2011 Jan; 43(1):18-22. PubMed ID: 21339541
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic effect of L-ornithine-L-aspartate on liver cirrhosis complicated by hepatic encephalopathy].
Chen MF; Li RC; Chen CH; Gao XC
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):718-9, 722. PubMed ID: 15958319
[TBL] [Abstract][Full Text] [Related]
5. [Detection of subclinical and overt hepatic encephalopathy and treatment control after L-ornithine-L-aspartate medication by magnetic resonance spectroscopy ((1)H-MRS)].
Hass HG; Nägele T; Seeger U; Hösl F; Gregor M; Kaiser S
Z Gastroenterol; 2005 Apr; 43(4):373-8. PubMed ID: 15830303
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of oral L-ornithine L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy.
Blanco Vela CI; Poo Ramírez JL
Ann Hepatol; 2011 Jun; 10 Suppl 2():S55-9. PubMed ID: 22228883
[TBL] [Abstract][Full Text] [Related]
7. [Because hepatic encephalopathy is a frequent contributing factor. Patients with liver cirrhosis are poorer drivers].
MMW Fortschr Med; 2003 Nov; 145(47):61. PubMed ID: 14725039
[No Abstract] [Full Text] [Related]
8. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
9. [Hepatic encephalopathy. L-ornithine-L-aspartate stimulate detoxification capacity of the liver].
Ameri AA
MMW Fortschr Med; 2010 Jun; 152(22):42-3. PubMed ID: 20590033
[No Abstract] [Full Text] [Related]
10. Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy.
Kircheis G; Lüth S
Drugs; 2019 Feb; 79(Suppl 1):23-29. PubMed ID: 30706424
[TBL] [Abstract][Full Text] [Related]
11. [Chronic liver diseases. Hepatic encephalopathy too frequently overlooked?].
MMW Fortschr Med; 2000 Jun; 142(25):56-7. PubMed ID: 10920673
[No Abstract] [Full Text] [Related]
12. [HEPATIC ENCEPHALOPATHY AND TISSUE ZINC LEVELS IN LIVER DISEASE, DIAGNOSIS AND TREATMENT].
Plotnikova EY; Baranova EN; Maksimov SA
Eksp Klin Gastroenterol; 2015; (7):46-54. PubMed ID: 26817122
[TBL] [Abstract][Full Text] [Related]
13. [The response to combined therapy of hepatic encephalopathy in patients with hepatic cirrhosis].
Maev IV; V'iuchnova ES; Lebedeva EG; Iakovenko EI; Dicheva DT
Klin Med (Mosk); 2002; 80(5):42-5. PubMed ID: 12087887
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis.
Schmid M; Peck-Radosavljevic M; König F; Mittermaier C; Gangl A; Ferenci P
Liver Int; 2010 Apr; 30(4):574-82. PubMed ID: 20456040
[TBL] [Abstract][Full Text] [Related]
15. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy.
Ahmad I; Khan AA; Alam A; Dilshad A; Butt AK; Shafqat F; Malik K; Sarwar S
J Coll Physicians Surg Pak; 2008 Nov; 18(11):684-7. PubMed ID: 18983791
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effects of L-ornithine L-aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta-analysis.
Butterworth RF
Metab Brain Dis; 2020 Jan; 35(1):75-81. PubMed ID: 31338724
[TBL] [Abstract][Full Text] [Related]
17. [Prevention and treatment of hepatic encephalopathy].
Sivolap YP
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(10):144-147. PubMed ID: 29171503
[TBL] [Abstract][Full Text] [Related]
18. [Pathogenesis and therapy of exogenous hepatic coma].
Leonhardt H
Fortschr Med; 1973 Jan; 91(1):35-8. PubMed ID: 4699340
[No Abstract] [Full Text] [Related]
19. [Hepatic encephalopathy and liver transplantation].
Fehérvári I; Nemes B; Görög D; Gerlei Z; Kóbori L
Magy Seb; 2012 Apr; 65(2):58-62. PubMed ID: 22512880
[TBL] [Abstract][Full Text] [Related]
20. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study.
Stauch S; Kircheis G; Adler G; Beckh K; Ditschuneit H; Görtelmeyer R; Hendricks R; Heuser A; Karoff C; Malfertheiner P; Mayer D; Rösch W; Steffens J
J Hepatol; 1998 May; 28(5):856-64. PubMed ID: 9625322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
